Finasteride (Synonyms: 非那雄胺; MK-906)

目錄號: HY-13635 純度: 99.97%: FAQs
Data Sheet SDS COA 產(chǎn)品使用指南技術(shù)支持

Finasteride (MK-906) 是一種具有口服活性的競爭性 5α-還原酶 (5α-reductase) 抑制劑，對 II 型 5α-還原酶的 IC₅₀ 值為 4.2 nM。Finasteride 對 II 型 5α-還原酶的親和力比對 I 型酶高約 100 倍。Finasteride 可用于研究前列腺增生 (BPH) 和雄激素性脫發(fā)。

MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報，我們不為任何個人用途提供產(chǎn)品和服務(wù)

Finasteride Chemical Structure

CAS No. : 98319-26-7

1. 客戶無需承擔(dān)相應(yīng)的運輸費用。

2. 同一機(jī)構(gòu)（單位）同一產(chǎn)品試用裝僅限申領(lǐng)一次，同一機(jī)構(gòu)（單位）一年內(nèi)

可免費申領(lǐng)三個不同產(chǎn)品的試用裝。

3. 試用裝只面向終端客戶。

規(guī)格	價格	是否有貨
10 mM * 1 mL in DMSO	￥563	In-stock
100 mg	￥512	In-stock
200 mg	￥880	In-stock
500 mg		詢價
1 g		詢價

or 大包裝詢價

* Please select Quantity before adding items.

Customer Review

Other Forms of Finasteride:

MCE 顧客使用本產(chǎn)品發(fā)表的 4 篇科研文獻(xiàn)

•Phytomedicine. 2023 Aug 25, 155048.
•J Transl Med. 2023 Feb 2;21(1):71. [Abstract]
•Sci Rep. 2019 Dec 23;9(1):19703. [Abstract]
•J Pain. 2019 May;20(5):577-591. [Abstract]

Finasteride 相關(guān)產(chǎn)品

•相關(guān)化合物庫:

•同靶點產(chǎn)品:

•同靶點蛋白產(chǎn)品:

生物活性
純度 & 產(chǎn)品資料
參考文獻(xiàn)

生物活性

Finasteride (MK-906) is an orally active and competitive 5α-reductase inhibitor, with an IC₅₀ of 4.2 nM for type II 5α-reductase. Finasteride has approximately a 100-fold greater affinity for type II 5α-reductase enzyme than for the type I enzyme. Finasteride can be used for the research of benign prostatic hyperplasia (BPH) and androgenic alopecia^[1]^[2]^[3].

IC₅₀ & Target

IC50: 4.2 nM (type II 5α-reductase)^[1]

細(xì)胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
DU-145	IC₅₀	13.53 μM Compound: Finasteride	Cytotoxicity against human DU145 cells assessed as growth inhibition after 24 hrs by CCK8 assay Cytotoxicity against human DU145 cells assessed as growth inhibition after 24 hrs by CCK8 assay	[PMID: 29615343]
DU-145	IC₅₀	14.53 μM Compound: Finasteride	Antiproliferative activity against human DU145 cells after 24 hrs by CCK-8 assay Antiproliferative activity against human DU145 cells after 24 hrs by CCK-8 assay	[PMID: 30482547]
DU-145	IC₅₀	3.9 μM Compound: Finasteride	Cytotoxicity against Homo sapiens (human) DU145 cells after 48 hr by MTT assay Cytotoxicity against Homo sapiens (human) DU145 cells after 48 hr by MTT assay	10.1007/s00044-010-9393-3
DU-145	IC₅₀	3.9 μM Compound: Finasteride	Antiproliferative activity against human DU145 cells assessed as growth inhibition after 48 hrs by MTT assay Antiproliferative activity against human DU145 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 20171759]
DU-145	IC₅₀	548 μM Compound: Finasteride	Cytotoxicity against human DU145 cells by rapid colorimetric assay Cytotoxicity against human DU145 cells by rapid colorimetric assay	[PMID: 26780831]
HEK293	IC₅₀	> 50 μM Compound: 1	Cytotoxicity against HEK293 cells after 24 hrs by MTT assay Cytotoxicity against HEK293 cells after 24 hrs by MTT assay	[PMID: 28693914]
HEK293	IC₅₀	218 nM Compound: 2a	In vitro inhibition of human Steroid 5-alpha-reductase type I in transfected 293 cells using [3H]- delta4-Androstenedione as substrate In vitro inhibition of human Steroid 5-alpha-reductase type I in transfected 293 cells using [3H]- delta4-Androstenedione as substrate	[PMID: 7739004]
HEK293	IC₅₀	30.3 nM Compound: 3	Inhibition of human type-2 5-alpha reductase expressed in HEK293 cells using [3H]-androstenedione as substrate after 30 mins by HPLC analysis Inhibition of human type-2 5-alpha reductase expressed in HEK293 cells using [3H]-androstenedione as substrate after 30 mins by HPLC analysis	[PMID: 22776417]
HEK293	IC₅₀	40 nM Compound: Finasteride	Inhibition of human 5alpha-2 reductase expressed in HEK293 cells assessed as suppression of conversion of [3]androstenedione incubated for 30 mins by radioactivity-based HPLC analysis Inhibition of human 5alpha-2 reductase expressed in HEK293 cells assessed as suppression of conversion of [3]androstenedione incubated for 30 mins by radioactivity-based HPLC analysis	[PMID: 26780831]
HEK293	IC₅₀	453 nM Compound: 3	Inhibition of human type-1 5-alpha reductase expressed in HEK293 cells using [3H]-androstenedione as substrate after 30 mins by HPLC analysis Inhibition of human type-1 5-alpha reductase expressed in HEK293 cells using [3H]-androstenedione as substrate after 30 mins by HPLC analysis	[PMID: 22776417]
HEK293	IC₅₀	453 nM Compound: Finasteride	Inhibition of human 5alpha-1 reductase expressed in HEK293 cells assessed as suppression of conversion of [3]androstenedione incubated for 30 mins by radioactivity-based HPLC analysis Inhibition of human 5alpha-1 reductase expressed in HEK293 cells assessed as suppression of conversion of [3]androstenedione incubated for 30 mins by radioactivity-based HPLC analysis	[PMID: 26780831]
LNCaP	IC₅₀	0.76 μM Compound: Finasteride	Inhibition of steroid 5-alpha-reductase in human LNCAP cells assessed as reduction in 5- dihydrotestosterone formation incubated for 60 mins by LC-MS analysis Inhibition of steroid 5-alpha-reductase in human LNCAP cells assessed as reduction in 5- dihydrotestosterone formation incubated for 60 mins by LC-MS analysis	[PMID: 32040314]
LNCaP	IC₅₀	13.53 μM Compound: Finasteride	Antiproliferative activity against human LNCAP cells after 24 hrs by CCK-8 assay Antiproliferative activity against human LNCAP cells after 24 hrs by CCK-8 assay	[PMID: 30482547]
LNCaP	IC₅₀	14.53 μM Compound: Finasteride	Cytotoxicity against human LNCAP cells assessed as growth inhibition after 24 hrs by CCK8 assay Cytotoxicity against human LNCAP cells assessed as growth inhibition after 24 hrs by CCK8 assay	[PMID: 29615343]
LNCaP	IC₅₀	19.8 μg/mL Compound: Finasteride	Inhibitory activity against 5-alpha-reductase type 1 in cell culture system using LNCaP cells (androgen-sensitive human prostatic cancer cell line) Inhibitory activity against 5-alpha-reductase type 1 in cell culture system using LNCaP cells (androgen-sensitive human prostatic cancer cell line)	[PMID: 11527731]
LNCaP	IC₅₀	53 μM Compound: Finasteride	Inhibitory activity against 5-alpha-reductase type 1 in cell culture system using LNCaP cells (androgen-sensitive human prostatic cancer cell line) Inhibitory activity against 5-alpha-reductase type 1 in cell culture system using LNCaP cells (androgen-sensitive human prostatic cancer cell line)	[PMID: 11527731]
Macrophage	IC₅₀	28.2 μM Compound: Finasteride	Cytotoxicity against Balb/C mouse macrophages assessed as cell viability after 24 hrs by MTT assay Cytotoxicity against Balb/C mouse macrophages assessed as cell viability after 24 hrs by MTT assay	[PMID: 20171759]
MCF7	IC₅₀	44.14 μM Compound: 1	Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay	[PMID: 28693914]
MDA-MB-231	IC₅₀	> 50 μM Compound: 1	Cytotoxicity against human MDA-MB-231 cells after 24 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 24 hrs by MTT assay	[PMID: 28693914]
PC-3	IC₅₀	> 80 μM Compound: 1	Cytotoxicity against human PC3 cells after 48 hrs by MTT assay Cytotoxicity against human PC3 cells after 48 hrs by MTT assay	[PMID: 28757062]
PC-3	IC₅₀	17.8 μM Compound: Finasteride	Antiproliferative activity against AR-deficient human PC3 cells assessed as reduction in cell viability after 24 hrs by CCK-8 assay Antiproliferative activity against AR-deficient human PC3 cells assessed as reduction in cell viability after 24 hrs by CCK-8 assay	[PMID: 31493989]
PC-3	IC₅₀	17.8 μM Compound: Finasteride	Antiproliferative activity against human PC3 cells after 24 hrs by CCK-8 assay Antiproliferative activity against human PC3 cells after 24 hrs by CCK-8 assay	[PMID: 30482547]
PC-3	IC₅₀	17.83 μM Compound: Finasteride	Cytotoxicity against human PC3 cells assessed as growth inhibition after 24 hrs by CCK8 assay Cytotoxicity against human PC3 cells assessed as growth inhibition after 24 hrs by CCK8 assay	[PMID: 29615343]

體外研究
(In Vitro)

Finasteride (10 μM；6-24 小時) 誘導(dǎo) PC-3 細(xì)胞中 HO-1 和 Nrf2 蛋白的表達(dá)^[2]。
Finasteride降低 P. crustosum 中的 [³H]睪酮 (T) 到 [³H]二氫睪酮 (DHT)。^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[2]

Cell Line:	PC-3, DU-145, and LNCaP cells
Concentration:	10 μM
Incubation Time:	6, 12, 24 h
Result:	Increased the expression of HO-1 protein in a time-dependent manner in PC-3 cells. Induced the expression of Nrf2 protein in DU-145 and PC-3 cells, but not in LNCaP cells.

體內(nèi)研究
(In Vivo)

Finasteride (0.1-0.5 mg/kg；每天口服一次，持續(xù) 16 周) 可減小 BPH 犬的前列腺大小，而不會對精液質(zhì)量或血清睪酮濃度產(chǎn)生不利影響^[3]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male dogs with spontaneous BPH (2.7-11 years old; 10.3-49 kg)^[3]
Dosage:	0.1-0.5 mg/kg
Administration:	P.o. once daily for 16 weeks
Result:	Decreased prostatic diameter (20%), prostatic volume (43%), and serum DHT concentration (58%). Decreased semen volume but did not adversely effect on semen quality or serum testosterone concentration. No adverse effects on dogs.

Clinical Trial

分子量

372.54

Formula

C₂₃H₃₆N₂O₂

CAS 號

98319-26-7

性狀

固體

顏色

White to off-white

中文名稱

非那雄胺；非那斯特萊；非那司提；非那甾胺

運輸條件

Room temperature in continental US; may vary elsewhere.

儲存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

溶解性數(shù)據(jù)

細(xì)胞實驗：

DMSO 中的溶解度 : 100 mg/mL (268.43 mM; 超聲助溶 (<60°C); 吸濕的 DMSO 對產(chǎn)品的溶解度有顯著影響，請使用新開封的 DMSO)

配制儲備液

濃度溶劑體積質(zhì)量	1 mg	5 mg	10 mg

1 mM	2.6843 mL	13.4214 mL	26.8428 mL
5 mM	0.5369 mL	2.6843 mL	5.3686 mL
10 mM	0.2684 mL	1.3421 mL	2.6843 mL

查看完整儲備液配制表

* 請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；一旦配成溶液，請分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。
儲備液的保存方式和期限：-80°C, 2 years; -20°C, 1 year。-80°C儲存時，請在2年內(nèi)使用， -20°C儲存時，請在1年內(nèi)使用。

摩爾計算器
稀釋計算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

濃度 _(start)

體積 _(start)

濃度 _(final)

體積 _(final)

動物實驗：

請根據(jù)您的實驗動物和給藥方式選擇適當(dāng)?shù)娜芙夥桨浮?

以下溶解方案都請先按照 In Vitro 方式配制澄清的儲備液，再依次添加助溶劑：
——為保證實驗結(jié)果的可靠性，澄清的儲備液可以根據(jù)儲存條件，適當(dāng)保存；體內(nèi)實驗的工作液，建議您現(xiàn)用現(xiàn)配，當(dāng)天使用；
以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的方式助溶

方案一

請依序添加每種溶劑： 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.71 mM); 澄清溶液

此方案可獲得 ≥ 2.5 mg/mL（飽和度未知）的澄清溶液。
以 1 mL 工作液為例，取 100 μL 25.0 mg/mL 的澄清 DMSO 儲備液加到 900 μL 20% 的 SBE-β-CD 生理鹽水水溶液中，混合均勻。
2 g SBE-β-CD（磺丁基醚 β-環(huán)糊精）粉末定容于 10 mL 的生理鹽水中，完全溶解至澄清透明。
方案二

請依序添加每種溶劑： 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (6.71 mM); 澄清溶液

此方案可獲得 ≥ 2.5 mg/mL（飽和度未知）的澄清溶液，此方案實驗周期在半個月以上的動物實驗酌情使用。
以 1 mL 工作液為例，取 100 μL 25.0 mg/mL 的澄清 DMSO 儲備液加到 900 μL玉米油中，混合均勻。

以下溶解方案，請直接配制工作液。建議現(xiàn)用現(xiàn)配，在短期內(nèi)盡快用完。以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的方式助溶。

方案一

請依序添加每種溶劑： 50% PEG300 50% Saline
Solubility: 2 mg/mL (5.37 mM); 懸濁液; 超聲助溶

動物溶解方案計算器

請輸入動物實驗的基本信息：

給藥劑量

mg/kg

動物的平均體重

每只動物的給藥體積

μL

動物數(shù)量

只

由于實驗過程有損耗，建議您多配一只動物的量

請輸入您的動物體內(nèi)配方組成：

DMSO +

Tween-80 +

Saline

如果您的動物是免疫缺陷鼠或者體弱鼠，建議 DMSO 中的在最后工作液體系中的占比盡量不超過 2%。

方案所需 助溶劑 包括：DMSO，，均可在 MCE 網(wǎng)站選購。，Tween 80，均可在 MCE 網(wǎng)站選購。

計算結(jié)果

工作液所需濃度 : mg/mL

儲備液配制方法 : mg 藥物溶于 μL DMSO（母液濃度為 mg/mL）。

您所需的儲備液濃度超過該產(chǎn)品的實測溶解度，以下方案僅供參考，如有需要，請與 MCE 中國技術(shù)支持聯(lián)系。

動物實驗體內(nèi)工作液的配制方法 : 取 μL DMSO 儲備液，加入 μL 。 μL ，混合均勻至澄清，再加 μL Tween 80，混合均勻至澄清，再加 μL 生理鹽水。

連續(xù)給藥周期超過半月以上，請謹(jǐn)慎選擇該方案。

請確保第一步儲備液溶解至澄清狀態(tài)，從左到右依次添加助溶劑。您可采用超聲加熱（超聲清洗儀，建議頻次 20-40 kHz），渦旋吹打等方式輔助溶解。

純度 & 產(chǎn)品資料

純度: 99.97%

選擇批次：

Data Sheet (641 KB) SDS (393 KB)

COA (291 KB) LCMS (95 KB)

產(chǎn)品使用指南 (1538 KB)

參考文獻(xiàn)

[1]. Flores E, et, al. Steroid 5alpha-reductase inhibitors. Mini Rev Med Chem. 2003 May;3(3):225-37. [Content Brief]

[2]. Yun DK, et, al. Finasteride Increases the Expression of Hemoxygenase-1 (HO-1) and NF-E2-Related Factor-2 (Nrf2) Proteins in PC-3 Cells: Implication of Finasteride-Mediated High-Grade Prostate Tumor Occurrence. Biomol Ther (Seoul). 2013 Jan;21(1):49-53. [Content Brief]

[3]. Sirinarumitr K, et, al. Effects of finasteride on size of the prostate gland and semen quality in dogs with benign prostatic hypertrophy. J Am Vet Med Assoc. 2001 Apr 15;218(8):1275-80. [Content Brief]

Finasteride 相關(guān)分類

完整儲備液配制表

可選溶劑	濃度溶劑體積質(zhì)量	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.6843 mL	13.4214 mL	26.8428 mL	67.1069 mL
	5 mM	0.5369 mL	2.6843 mL	5.3686 mL	13.4214 mL
	10 mM	0.2684 mL	1.3421 mL	2.6843 mL	6.7107 mL
	15 mM	0.1790 mL	0.8948 mL	1.7895 mL	4.4738 mL
	20 mM	0.1342 mL	0.6711 mL	1.3421 mL	3.3553 mL
	25 mM	0.1074 mL	0.5369 mL	1.0737 mL	2.6843 mL
	30 mM	0.0895 mL	0.4474 mL	0.8948 mL	2.2369 mL
	40 mM	0.0671 mL	0.3355 mL	0.6711 mL	1.6777 mL
	50 mM	0.0537 mL	0.2684 mL	0.5369 mL	1.3421 mL
	60 mM	0.0447 mL	0.2237 mL	0.4474 mL	1.1184 mL
	80 mM	0.0336 mL	0.1678 mL	0.3355 mL	0.8388 mL
	100 mM	0.0268 mL	0.1342 mL	0.2684 mL	0.6711 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

您最近查看的產(chǎn)品:

產(chǎn)品名稱：

* 需求量：

* 客戶姓名：

* Email：

* 電話：

* 公司或機(jī)構(gòu)名稱：

留言給我們：

MedChemExpress (MCE) 只為有資質(zhì)的科研機(jī)構(gòu)、醫(yī)藥企業(yè)基于科學(xué)研究或藥證申報的用途提供醫(yī)藥研發(fā)服務(wù)，不為任何個人或者非科研性質(zhì)的、非用于藥證申報使用等其他用途提供服務(wù)。	站點地圖隱私聲明
滬ICP備15051369號-4 上海工商滬公網(wǎng)安備31011502019417 滬(浦)應(yīng)急管危經(jīng)許[2021]201709(QFYS) 營業(yè)執(zhí)照（三證合一）
Copyright ? 2013-2025 MedChemExpress. All Rights Reserved.

MedChemExpress (MCE) 只為有資質(zhì)的科研機(jī)構(gòu)、醫(yī)藥企業(yè)基于科學(xué)研究或藥證申報的用途提供醫(yī)藥研發(fā)服務(wù)，不為任何個人或者非科研性質(zhì)的、非用于藥證申報使用等其他用途提供服務(wù)。

站點地圖隱私聲明

滬ICP備15051369號-4

上海工商

滬公網(wǎng)安備31011502019417

滬(浦)應(yīng)急管危經(jīng)許[2021]201709(QFYS)

營業(yè)執(zhí)照（三證合一）

成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Finasteride (Synonyms: 非那雄胺; MK-906)

Customer Review

Other Forms of Finasteride:

MCE 顧客使用本產(chǎn)品發(fā)表的 4 篇科研文獻(xiàn)